Rinvoq ER 45 MG tablet UU 28S
Ended Awarded Last action
- Contract number
- SPE2DR26FN1H8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $96,056
Award facts
- Contract value 100% obligated
- $96,055.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $96,055.75 to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of RINVOQ ER 45 mg tablets (28-tablet units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of January 30, 2026. The vendor will perform from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2031.
The Cencora/AmerisourceBergen IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. The company supplies critical pharmaceutical products to the Defense Health Agency, U.S. Coast Guard, and other federal government healthcare systems. RINVOQ (upadacitinib) is a targeted synthetic immunosuppressant used in the treatment of rheumatoid arthritis and other autoimmune conditions, reflecting the diversity of medications delivered through this pharmaceutical prime vendor contract.
Quick answers
Who was awarded contract SPE2DR26FN1H8?
SPE2DR26FN1H8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FN1H8 worth?
The government has obligated $96,056 on SPE2DR26FN1H8.
Is contract SPE2DR26FN1H8 an order under another contract?
Yes. SPE2DR26FN1H8 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FN1H8 competed?
The extent of competition for SPE2DR26FN1H8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award